Stifel Nicolaus analyst Stephen Willey has maintained their bullish stance on BCAX stock, giving a Buy rating yesterday.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Stephen Willey has given his Buy rating due to a combination of factors related to Bicara Therapeutics Inc.’s promising data in the treatment of HPV-negative patients with 1L SCCHN. The company has shown an improved complete response rate of 21% and a 12-month overall survival rate of 61%, which are encouraging indicators of efficacy. Additionally, the median overall survival for these patients has exceeded 20 months, providing a significant advantage over historical data for single-agent pembrolizumab.
Furthermore, the ongoing trials and upcoming presentations at ASCO are expected to provide more detailed efficacy, safety, and translational data, which could further support the positive outlook. The management’s intention to release more granular safety and tolerability data, along with mature overall survival and duration of response outcomes, adds to the potential for continued investor interest. Despite some competitive pressure from MRUS, the differentiated data sets and the potential for further positive updates underpin Willey’s Buy recommendation.
In another report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $36.00 price target.
BCAX’s price has also changed moderately for the past six months – from $18.090 to $15.660, which is a -13.43% drop .